Status
Conditions
Treatments
About
PET / CT examination using [18F] FAPI-74 is performed on patients diagnosed with malignant tumor, and the pathological condition is determined by comparing with FDG-PET/CT examination of conventional diagnostic imaging.
Full description
Cancer stroma accounts for more than 90% of all tumors, and cancer-related fibroblasts (CAFs) play an important role in the growth and progression of cancer. FAP expressed in CAF has been found to be expressed in many cancers, and [68Ga] FAPI-04 and [18F] FAPI-74, which are PET diagnostic agents for FAP ligand FAPI, have been used all over the world. The purpose of this study is to perform PET / CT using [18F] FAPI-74 injection for patients diagnosed with malignant tumors, mainly pancreatic cancer and gastric cancer to evaluate the pathology in detail by comparing with the FDG-PET/CT.
Enrollment
Sex
Volunteers
Inclusion criteria
Patients who meet any of the following conditions.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
200 participants in 1 patient group
Loading...
Central trial contact
Tadashi Watabe, M.D., Ph.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal